
- /
- Supported exchanges
- / US
- / TVGNW.NASDAQ
Tevogen Bio Holdings Inc (TVGNW NASDAQ) stock market data APIs
Tevogen Bio Holdings Inc Financial Data Overview
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Tevogen Bio Holdings Inc data using free add-ons & libraries
Get Tevogen Bio Holdings Inc Fundamental Data
Tevogen Bio Holdings Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -34 241 900
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tevogen Bio Holdings Inc News

Tevogen expands headquarters in Warren, New Jersey
Tevogen (TVGN) announced the execution of a lease agreement to expand its corporate headquarters in Warren, New Jersey, more than doubling its footprint. The expanded space will centralize cross-funct...


Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Tevogen Bio Inc WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its a...

Tevogen Peports Plans to Increase the Target Population for TVGN 489
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above.Tevogen reports plans to increase th...

Tevogen sees launch year oncology business revenue $1B
Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The forecas...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.